Compare

Axcelis Technologies/$ACLS

1D1W1M3M6MYTD1Y5YMAX

About Axcelis Technologies

Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
Ticker
$ACLS
Sector
Semiconductors
Primary listing
NASDAQ
Employees
1,465

ACLS Metrics

BasicAdvanced
$3.1B
29.50
$3.36
1.89
-

What the Analysts think about ACLS

Analyst ratings (Buy, Hold, Sell) for Axcelis Technologies stock.
Analyst projections of the future price of Axcelis Technologies stock.

Bulls say / Bears say

Bookings reached $222 million in the third quarter, the highest since late 2023, and the 1.5 book-to-bill lifted backlog to $531 million. That points to strengthening demand ahead of shipments. (The Motley Fool)
Customer Support and Integration revenue hit a quarterly record of $93 million, supported by a larger installed base and higher tool use. This growing aftermarket business can provide a steadier revenue stream alongside equipment sales. (The Motley Fool)
Axcelis says new implant technologies are gaining traction, including advanced-channeling systems selected by multiple tier-one customers and multiple orders for its proton implant solution. These wins could broaden its opportunities in power semiconductors as customer investment recovers. (The Motley Fool)
Profit and cash generation weakened over the first nine months: net income fell to $70.3 million from $85.9 million, while operating cash flow dropped to $76.7 million from $124.9 million. Third-quarter gross margin also slipped year on year, showing that higher sales have not yet translated into stronger underlying returns. (StockTitan, Axcelis Technologies)
China accounted for 46% of third-quarter revenue, leaving Axcelis heavily exposed to one market. A pullback in Chinese customer spending or changes in the policy environment could therefore weigh materially on sales. (The Motley Fool)
The planned Veeco merger has been pushed to the end of the first quarter of 2027, with Chinese regulatory clearance still outstanding and a fresh US antitrust filing needed. Further delay or failure to secure approval could postpone the expected benefits of the combination. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

ACLS Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ACLS Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing ACLS

AllUSDEURGBP
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.